The drug, known as Sprycel, would be used to treat chronic myeloid leukaemia (CML) in patients who have developed a resistance or intolerance to Gleevec. CML represents 14 percent of all adult leukaemia's, according to the FDA.

Advertisement

Bristol-Myers Squibb, which makes Sprycel, also got the panel's blessing to use the drug to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia, the AP reported.

The FDA is expected to decide whether to approve Sprycel by June 28; the advisory panel met in Atlanta to coincide with the American Society of Clinical Oncology (ASCO) annual meeting, which is being held in that same city. – (HealthDayNews)

Visit our Cancer Centre for more information.

June 2006
 

Print this article on

Rate this article Poor 1 2 3 4 5 Excellent

JOBS

Civil Engineering Technician Gauteng - Johannesburg Financial Manager R380,000-400,000 Per Annum Cost To Company Gauteng - West Rand Treasury Specialist R300,000-380,000 Per Annum Cost To Company Gauteng - Johannesburg JAVA DEVELOPER (YL028 – 04/09) Gauteng DELPHI DEVELOPER (YL023 – 04/09) R320,000-360,000 Per Annum Cost To Company Market Related Gauteng Senior and Lead .NET Developers (C#.NET, Arc, Design, Code.) R300,000-600,000 Per Annum Cost To Company Gauteng - Johannesburg A C# Developer (C Sharp Developer) Gauteng - Johannesburg A C++ Developer (Software Developer) Gauteng - Pretoria Find more jobs Register your CV Post a job